Table 1 Baseline data of girls with CPP

CA (years)

8.42 (7.90–8.92)

8.50 (8.17–8.92)

0.375

Developmental age (years)

7.00 (6.33–7.52)

7.25 (6.50–7.75)

0.022

BA (years)

9.29 (8.83–10.00)

10.00(9.83–11.00)

< 0.001

Disease course (years)

1.25 (0.89–2.00)

1.25 (0.92–2.00)

0.730

Height(cm)

135.05(130.75–138.03)

137.00(132.00–141.05)

0.009

Weight(kg)

30.00(27.10–34.10)

32.00(28.71–36.46)

0.002

BMI (kg/m²)

16.50 (15.66–17.79)

17.37 (15.87–18.76)

0.007

Height SDS

1.00(0.31–1.87)

1.35 (0.45–2.20)

0.074

BMI SDS

0.26(-0.08–0.73)

0.4954(0.04–0.99)

0.010

IGF1 SDS

0.54(0.13–1.03)

1.1352(0.57–1.62)

< 0.001

25OHD (ng/ml)

16.10 ± 6.84

15.78 ± 6.91

0.369

Peak LH/FSH ratio

0.76 (0.48–1.38)

1.42 (1.00–2.02)

< 0.001

BMD

0.10 (− 0.30–0.60)

0.20 ((− 0.20–0.70)

0.207

IGF-1 level (ng/ml)

287.00 (220.50–346.50)

358.50 (291.75–419.00)

< 0.001

Baseline LH level (IU/L)

0.72 (0.36–1.43)

1.12 (0.58–2.11)

< 0.001

Peak LH level (IU/L)

9.19 (6.54–20.27)

20.89 (11.21–30.41)

< 0.001

Baseline FSH level (IU/L)

4.73 ± 2.34

4.46 ± 2.20

0.483

Peak FSH level (IU/L)

13.35 (10.52–19.96)

13.15 (10.72–17.41)

0.903

Advanced bone age (years)

0.87 (0.48–1.42)

1.75 (1.42–2.08)

< 0.001

Tanner stage of breast development

< 0.001

 B2

29 (25.5%)

30 (13.3%)

 B3

73 (64.0%)

164 (72.6%)

 B4

12 (10.5%)

32 (14.1%)